Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 Post ContentkptiRead More You might also be interested in reading Ethereum Rallies Since Gas Fees Drop. August 11, 2025 In Mainstream ← Previous post Next post →